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Abstract
Background: Atopic eczema (atopic dermatitis, AD) is characterized by disrupted skin 
barrier associated with elevated skin pH and skin microbiome dysbiosis, due to high 
Staphylococcus aureus loads, especially during flares. Since S aureus shows optimal 
growth at neutral pH, we investigated the longitudinal interplay between these fac-
tors and AD severity in a pilot study.
Method: Emollient (with either basic pH 8.5 or pH 5.5) was applied double-blinded 
twice daily to 6 AD patients and 6 healthy (HE) controls for 8 weeks. Weekly, skin 
swabs for microbiome analysis (deep sequencing) were taken, AD severity was as-
sessed, and skin physiology (pH, hydration, transepidermal water loss) was measured.
Results: Physiological, microbiome, and clinical results were not robustly related to 
the pH of applied emollient. In contrast to longitudinally stable microbiome in HE, 
S aureus frequency significantly increased in AD over 8 weeks. High S aureus abun-
dance was associated with skin pH 5.7-6.2. High baseline S aureus frequency pre-
dicted both increase in S aureus and in AD severity (EASI and local SCORAD) after 
8 weeks.
Conclusion: Skin pH is tightly regulated by intrinsic factors and limits the abundance 
of S aureus. High baseline S aureus abundance in turn predicts an increase in AD 
severity over the study period. This underlines the importance and potential of sus-
tained intervention regarding the skin pH and urges for larger studies linking skin pH 
and skin S aureus abundance to understand driving factors of disease progression.
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1  | INTRODUC TION
Atopic eczema (atopic dermatitis, AD) is the most common chronic 
inflammatory skin disease in children and accepted as risk factor for 
the development of allergic sensitization.1,2 Barrier disruption is one 
central pathophysiological parameter underlying AD. Skin barrier and 
skin homeostasis are formed by microbiome, chemical, physical, im-
mune, and neurological barriers that form an interactive network.3 
Within this tightly regulated network, skin pH holds a central role. 
AD is associated with an elevated skin pH, especially during disease 
flares compared with the naturally more acidic pH in healthy skin.4 
Furthermore, the skin microbiome is dysbalanced and its diversity re-
duced typically due to an elevated Staphylococcus aureus load, which 
correlates with disease severity.5–7 However, the interplay between 
the skin microbiome, physiological skin barrier properties, and AD se-
verity especially in a longitudinally setting is not yet well-understood.
The acidic skin pH is crucial for a functional skin barrier.3,4,8 
Nevertheless, the data of a “physiologic” skin pH vary in the lit-
erature most likely due to endogenous and exogenous factors 
influencing skin pH as well as differences in the measurement 
procedure. On forearms, foreheads, or cheeks of healthy volun-
teers, a rather acidic pH (<6) was measured in several studies.9 The 
elevated skin pH in AD is linked to disease severity.10,11 As part 
of the cutaneous connected network, the skin pH regulates the 
activity of certain enzymes, such as serine proteases and β-gluco-
cerebrosidases. These enzymes are involved in the regulation of 
cohesion proteins and in lipid processing in the stratum corneum 
of the epidermis.3,8 Lower pH values are associated with less scal-
ing and higher hydration levels, whereas increased skin pH can im-
pair stratum corneum integrity and skin barrier function.8,9 Thus, 
the altered skin pH may contribute to the disrupted skin barrier 
observed in AD patients.
Furthermore, loss-of-function mutations of the barrier protein gene 
filaggrin (FLG) are known risk factors in the pathogenesis of AD.12,13 A 
disruption of the skin barrier is also associated with higher transepider-
mal water loss (TEWL), which may facilitate the penetration of aller-
gens leading to inflammation and worsening of the disease.14,15 High 
TEWL and low hydration are commonly observed in AD skin and often 
associated with an elevated skin pH.16 Interestingly, FLG degradation 
products are skin pH reducing organic acids which act as natural mois-
turizing factors and reduce S aureus growth in vitro.17–20
Homeostatic skin microbiome is important to maintain host de-
fense against pathogens and is therefore another important part 
of the skin barrier.21–23 While healthy skin demonstrates high mi-
crobiome diversity, with Cutibacterium acnes and Staphylococcus 
epidermidis being the most common species, in AD skin diversity is sig-
nificantly reduced due to S aureus dominance.21–23 Furthermore, the 
skin pH is part of the microenvironment regulating bacterial growth. 
At acidic (<5.5) pH growth of S epidermidis is enhanced, whereas the 
growth of S aureus and Propionibacteria is suppressed.9,24 S aureus in 
turn grows best at neutral (6-7) pH conditions.25
Considering both healthy and AD-related dysbalanced micro-
environments, we focused on the possibility of influencing skin pH 
through emollient application with different pH. Following our hy-
pothesis that an emollient with pH 5.5 supports physiological skin 
barrier functions and inhibits the growth of harmful S aureus, we per-
formed a longitudinal intervention pilot study with a comprehensive 
approach involving not only clinical but also skin physiological (pH, 
hydration, TEWL) and microbiome analysis. Additionally, we hypoth-
esized that skin pH and S aureus abundance effect changes in AD 
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In healthy individuals, skin microbiome is stable over 8 weeks, but not in atopic dermatitis patients who show a significant increase in 
Staphylococcus aureus over time. Skin pH of 5.7-6.2 allows the growth of S aureus in atopic dermatitis individuals. Higher S aureus abundance 
at baseline is a predictor for increased S aureus and AD severity at endpoint.
Abbreviations: AD, atopic dermatitis; HE, healthy.
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disease severity over time. This is to the best of our knowledge the 
first study of this nature.
2  | METHODS
2.1 | Study design
The study was designed as a double-blinded intra-individual com-
parison of two emollients that only differ in their pH values: either 
acidic (pH 5.5) or alkaline emollient (pH 8.5). Each emollient was ap-
plied on one randomized body side (left or right) within a certain 
test body region. Six healthy individuals (HE) and 6 AD patients 
were enrolled for the pilot study. Participants applied the emollients 
twice daily in the morning and evening and returned to the study 
center on weekly basis for clinical evaluation (Figure S1). The study 
was approved by the ethics committee of the Technical University 
of Munich (187/17S). All participants signed informed consent state-
ments. Examinations took place from October to December 2017 
(four HE: IDs 3-6 and four AD: IDs 11-14) and from April to June 
2018 (two HE: IDs 1 and 2 and two AD: IDs 15 and 16).
2.2 | Inclusion/exclusion criteria
A hypersensitive reaction against the study emollients was ex-
cluded by epicutaneous patch tests and assessment after 48 hours. 
Reddening or papulation of the skin led to exclusion. Exclusion crite-
ria were antibiotic treatment <14 days before the start of the study 
or application of steroids or calcineurin inhibitors within the region 
of interest or systemic use <7 days prior to the start of the study. 
Therefore, only AD patients with mild-to-moderate SCORAD < 40 
(min = 12.8, max = 37.6, average = 29.4) with comparable severity 
of eczema on both body sides in at least one body area, where study 
emollients were later applied later. Body test regions of HE were 
matched according to AD and were distributed as follows: 2× dorsal 
lower leg, 2× antecubital areas, 1× volar upper arm, and 1× volar 
shoulder. Study groups were matched in age and gender.
2.3 | Emollients and application procedure
All study emollients were provided by Sebapharma GmbH & Co. 
KG. Participants were asked not to use any other skin care products 
or topical treatment beside the study emollients in the determined 
body region. For the application of each emollient, a new glove was 
used each time. Emollients were applied widely in the test region in 
a field of about 10 × 15 cm. On average, 4.7 mg of emollient, com-
parable in both study groups and treatment arms, was applied per 
cm2. Time distance from measurements and samplings to the last 
emollient application was at least 3 hours and to the last shower at 
least 12 hours. Emollient pH was measured at the beginning and end 
of study period.
2.4 | Physiological measurements
Measurements were taken after an acclimatization period for 
the skin of 20 minutes at a mean room temperature of 22.2°C 
and a mean humidity of 46.6 g/m3. Transepidermal water loss 
(TEWL), hydration, and skin pH were measured with Tewameter® 
TM 300, Corneometer® CM 825, and Skin-pH-Meter PH905 by 
Courage + Khazaka Electronic GmbH. The mean out of 3 measure-
ments was taken for statistical analysis, respectively. General sever-
ity of AD was evaluated using objective SCORAD,26,27 EASI,28 or 
local symptoms within the test region (details Methods S1).
2.5 | Microbiome analysis
For microbiome analysis, skin swabs (Sigma-swab, MWE) were 
taken dry, rubbing 20 times in a field of 2 cm × 2 cm, and stored in 
500 μL Stool DNA Stabilizer Solution (Stratec) at −80°C and ana-
lyzed using 16S (variable region V1-V3, primers 27F-YM and 534R) 
amplicon-based next-generation sequencing. For DNA extraction, 
the QIAamp UCP Pathogen Kit (Qiagen) was used. Lysis was per-
formed using Precellys Evolution (Bertin Technologies®: Montigny-
le-Bretonneux, France). The 16S rRNA sequencing was performed 
on Illumina MiSeq® platform (Illumina Inc) using 2 × 300 bp pair-end 
reads (MiSeq® Reagent Kit v3 600 cycles; Illumina Inc). OTU cluster-
ing against the SILVA database was performed using CLC Genomics 
Workbench 11.0.1 and its microbial genomics module. After quality 
control (merging, chimera reduction), samples with less than 1000 
reads were excluded from analysis (2 samples from HE_ID_6, week 
1, 6 - pH 5.5 or pH 8.5, respectively). The α- and β-diversity and 
frequency of the top 10 families and species were analyzed based 
on the RHEA R-scripts published by Lagkouvardos et al 2017.29 
Optimized species annotation was performed using the algorithm of 
Bhattacharyya et al 2020.30 For detailed protocol, see Methods S1.
2.6 | Statistical analysis
Statistical significance of differences in continuous variable results 
between the HE and AD groups was assessed by the nonparametric 
Mann-Whitney test, while differences between the 2 emollient ap-
plications (left and right arms of the same patients) were assessed 
by the paired Wilcoxon nonparametric test. Since changes in skin 
microbiome were independent of the emollient pH, data from the 
2 body sides were combined for analyses of differences between 
AD and HE groups and longitudinal analysis. However, the results 
are qualitatively the same also when analyzed separately for each 
of the emollient applications. For longitudinal analysis, the mean of 
all measured physiological, clinical, and microbiome parameters of 
early (weeks 0-2), mid (weeks 3-5), and late (weeks 6-8) phases of 
the study was calculated for samples of each body side separately 
to reduce fluctuations in the data. Correlation between continu-
ous variables was assessed using the nonparametric Spearman rank 
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test. P-values were considered as significant at the alpha-error two-
tailed level of P < .05 and robustly significant with P < .03 over a few 
measurements. Unless otherwise stated, median values (with maxi-
mum and minimum) are shown in the figures. Statistical analysis and 




Participant groups were age- and gender-matched. Each group con-
sisted of 2 male and 4 female participants with a mean age of 43.5 
in HE and 43.35 in AD. All participants were Caucasian (Table S1).
3.2 | Skin pH buffered by intrinsic 
regulatory mechanisms
At baseline, both body sides exhibited similar skin pH (Figure 1A), 
TEWL (Figure 1B), and skin hydration (Figure 1C) in each of the study 
groups, AD and HE. During the intervention only at a few time points, 
slightly lower skin pH was measured in the pH 5.5–treated body sides 
compared with the pH 8.5–treated sides in both study groups. The 
difference in skin pH between treatment groups was statistically sig-
nificant after weeks 2, 5, and 7 in AD and only after week 6 in HE 
(P < .05). However, the skin pH did not reach emollient pH levels. No 
effect of the pH level of the emollient on TEWL (Figure 1B) or hydra-
tion (Figure 1C) was observed neither in HE nor in AD.
3.3 | Skin physiology differences between 
AD and HE
There was no significant difference in skin pH (Figure 1A) between HE 
and AD in this study, neither at baseline nor during the time course of 
the study. TEWL (Figure 1B) was significantly higher in AD (median 
over study period: 27.4) at all time points compared with HE (9.3) (Table 
S2). Skin hydration was generally lower in AD (AD 27.8, HE 46.6); how-
ever, at baseline the difference was not significant (Figure 1C).
Independent of the pH of the emollient, none of our study groups 
showed major changes in parameters of skin physiology compared 
with baseline values (week 0).
3.4 | Individual changes in disease severity of AD
At baseline, as well as at later time points, no difference in local 
SCORAD (Figure 1D) was seen between the pH 5.5- and pH 8.5–
treated body sides. Furthermore, compared to baseline, local 
SCORAD did not significantly change in the time course of the 
study. Whereas overall per group the scores for EASI and objec-
tive SCORAD remained stable from baseline to endpoint, some 
participants increased remarkably in objective SCORAD (5 of 6) and 
EASI (4 of 6) (Figure 1E,F).
3.5 | No differences in skin microbiome between 
application of emollient with pH 5.5 or 8.5
At baseline, no differences were detectable between the later dif-
ferently treated body sides in none of the study groups, neither in 
β-diversity (Figure S2) nor in α-diversity (Figure 2A,B). Analyzing the 
taxonomic composition at baseline, the top 10 families and species were 
generally comparable on both body sides in AD and HE (Figure 2D). 
Furthermore, no robust differences between the body sides due to 
emollient pH were seen in the microbiome α-diversity indices rich-
ness and evenness as well as on family (Figure 2A-D) and species levels 
(Table S3) at any time point. At endpoint, the global microbiome re-
mained unaltered irrespective of the emollient pH (Figure S2).
3.6 | Differences in the skin microbiome between 
HE and AD
Comparing the global microbiome of HE and AD at baseline, dif-
ferent clusters were visible, which remained throughout the study 
(Figure S2). No difference in α-diversity indices was seen at baseline. 
The main difference between AD and HE over time was higher S au-
reus abundance on species level and lower Micrococcaceae on family 
level in AD (Figure 2E, Table S3).
3.7 | Stable skin microbiome in HE contrasts 
increase in S aureus abundance in AD
Whereas richness and evenness were stable upon emollient ap-
plication in HE participants, the richness in AD patients increased 
significantly at all time points except for week 3 (P < .05) compared 
with baseline. Over time, the family of Lactobacillaceae significantly 
decreased in AD patients (Table S3). Whereas S aureus abundance 
increased significantly in all weeks except for week 3 compared with 
baseline in group AD, HE participants had no change in S aureus levels 
(Figure 2E). When looking at patient level, it becomes clear that only 
some AD patients have an increase in S aureus abundance (Figure 2F).
3.8 | Skin physiological parameters correlate among 
each other
Skin pH was positively correlated with TEWL (P < .05; r = .63 (early), 
r = .63 (mid) r = .65 (late)). Between skin pH and skin hydration, no 
significant correlation was detected; however, a negative association 
was visible (r = −.4 (early), r = −.45 (mid), r = −.5 (late)). Furthermore, 
TEWL and skin hydration were negatively correlated at early- and 
mid-time points (early: P < .05; r = −.63: mid: P < .05; r = −.69, late: 
P = .058; r = −.56) (Figure S3).
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3.9 | pH and hydration influences S aureus growth in 
AD patients
Staphylococcus aureus abundance higher than 10% was only found 
in the pH range of 5.7-6.2 (Figure 3 A-C), while lower or higher skin 
pH only allowed lower S aureus frequency. Increasing S aureus from 
early to mid- to late phases also occurred only in the same pH range, 
in association with higher local SCORAD. Whereas TEWL seemed to 
have no relation to S aureus abundance (Figure 3D-F), low hydration 
was associated with higher S aureus abundance in the early phase 
(r = −.66, P < .05), with the same trend observed in mid- and late 
phases (Figure 3G-I).
F I G U R E  1   Skin physiology and clinical scores. Emollient pH does not robustly affect skin physiology. Changes in physiological parameters 
(skin pH (A), transepidermal water loss (B), and skin hydration (C)) over the study period of 8 wk are shown as median (min, max) per group 
and treatment (AD 5.5 = orange, AD 8.5 = red, HE 5.5 = green, HE 8.5 = blue). In AD patients, changes in local AD severity in treated body 
sides (local SCORAD) are shown over 8 wk (D). Additionally, the general AD severity indexes objective SCORAD (E) and EASI (F) are shown 
at baseline (week 0) and at endpoint (week 8) of the observation period per AD patient. Significant difference between treatment (emollient 
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3.10 | High S aureus correlates with local 
severity of symptoms
High S aureus abundance was strongly correlated (r = .79, P < .01) with 
higher individual local SCORAD in mid and late phases of the study 
(Figure 4B,C), but not in early phase (Figure 4A). Generally, S aureus 
was lower in early phase and its increase in mid- and late phases was 
associated with an increase in local SCORAD (Figure 5A,B).
3.11 | Baseline S aureus abundance as predictive 
factor for increasing disease severity
Intriguingly, high S aureus abundance at baseline was correlated 
with an increase in S aureus from baseline to endpoint (r = .78, 
P < .01). Furthermore, increase in severity of EASI and local 
SCORAD could be predicted by baseline S aureus abundance. 
High baseline S aureus resulted in more severe worsening of AD 
F I G U R E  2   Skin microbiome. Skin microbiome is stable in HE, while in AD Staphylococcus aureus abundance significantly increases, 
independently of emollient pH. The α-diversity indices richness (A) and evenness (B) as well as S aureus abundance (E) are shown over the 
study period of 8 wk as median (min, max) per group and treatment (AD 5.5 = orange, AD 8.5 = red, HE 5.5 = green, HE 8.5 = blue). Top 10 
taxa at family level are shown for AD (C) and HE (D) separately for the treatments. Individual S aureus abundances of all AD participants are 
shown at early (weeks 0-2), mid (weeks 3-5), and late (weeks 6-8) phases of the study (F). P-values for comparison of treatments, groups, and 
to baseline are shown in the Table S3
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(change local SCORAD: P < .05; r = .59, change EASI: P < .05; 
r = .64). However, objective SCORAD changes were not correlated 
with baseline S aureus. In accordance, high baseline abundance of 
S aureus was correlated with high local SCORAD (r = .83, P < .001) 
and EASI (r = .86, P < .001), but not with objective SCORAD after 
8 weeks (Figure S4).
F I G U R E  3   Correlations of skin physiological parameters with Staphylococcus aureus abundance in AD patients. Skin pH of 5.7-6.2 and 
low hydration are associated with high S aureus abundance. S aureus abundance is shown as function of skin pH (A-C), TEWL (D-F), and skin 
hydration (G-I) at early, mid, and late time points. Colors correspond to local SCORAD values (green = mild (<5), yellow = moderate (5-8), 
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4  | DISCUSSION
This is the first study where frequent longitudinal measurement of 
skin microbiome was assessed in connection with skin physiology 
measurements and with AD disease severity during an interven-
tion with a skin emollient. Our data strongly suggest that the skin 
microbiome of healthy individuals is tightly regulated over time, in 
contrast to an instable microbiome in AD patients Strikingly, we 
found that the initial abundance of S aureus is predictive for future 
increase in S aureus abundances and in AD severity. Thus, individuals 
with high abundances of S aureus might be more likely to experi-
ence naturally occurring flares as previously hypothesized by us.31 
However, this conclusion is only based on a worsening of EASI and 
was not confirmed by objective SCORAD. However, it should be 
noted that upon study initiation patients stopped their usual treat-
ment and started the application of a new emollient. These changes 
in daily skin care habit may be considered as a possible reason for the 
worsening of AD, but anyway correlated with S aureus at baseline. 
F I G U R E  4   Clinical symptoms in 
the context of Staphylococcus aureus 
abundances in AD. Disease severity is 
correlated with S aureus abundance in mid 
and late phases of study. Local SCORAD 
of each individual and body side (black 
dots) is shown as function of S aureus 
abundance at early (A), mid (B), and late 
(C) time points. Significant correlations are 
marked with **P < .01
(A) (B) (C)
F I G U R E  5   Changes in microbiome 
and AD severity as function of baseline 
Staphylococcus aureus abundance. High 
baseline S aureus predicts worsening 
of AD severity. Changes (baseline to 
endpoint) in S aureus abundance (A), local 
SCORAD (B), EASI (C), and objective 
SCORAD (D) as function of baseline 
S aureus abundance in individual AD 
patients. Significant correlations are 
marked with *P < .05
(A) (B)
(C) (D)
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Interestingly, local AD severity worsening was not associated with 
the emollient pH.
With our results, we highlight once more the link between S au-
reus and AD severity.10,11,32 Some S aureus strains are potentially 
pathogenic and capable of expressing superantigens and enterotox-
ins,33,34 which lead to an inflammation cascade additionally dam-
aging the skin barrier,32 and linking S aureus abundance and clinical 
symptoms in AD.5,35,36 Increasing bacterial load or clonal expansion 
of pathogenic strains can play a role. In accordance, high S aureus 
abundances were associated with high severity of local clinical symp-
toms at mid and end of the study. However, at the early phase of the 
study, S aureus abundance was generally low and not correlated with 
local clinical symptoms, which might be due to the inclusion of only 
low-to-moderate AD patients in the study. Also, local SCORAD is 
highly subjective score and clinical symptoms can be related to other 
factors such as stress.37,38
There is much controversy about the effect of cosmetic, emol-
lients, and basis therapy in general on the skin microbiome and its di-
versity. Contrasting the stable microbiome in HE, richness increased 
in AD patients over the study period of 8 weeks using the emollient 
as described previously.39,40 Abundance of Micrococcaceae was 
significantly lower in AD patients in our study confirming previous 
results.41 Interestingly, the family Lactobacillaceae, which harbors 
probiotic species also considered for AD treatment, significantly de-
creased over the study period in AD patients.42,43 Lastly, S aureus 
was significantly more abundant in AD patients than HE as previ-
ously described.10,11,32
We found the highest counts of S aureus in a pH range be-
tween pH 5.7 and pH 6.2, whereas higher or lower pH value seems 
to limit its growth. According to the literature, the optimum pH 
for the growth of S aureus is between pH 6 and pH 7, which un-
fortunately cannot be tested in our study since neutral pH was 
only represented by one participant with comparable low S aureus 
abundance. Furthermore, it is likely that other factors than pH 
control S aureus growth, as in the same pH range also low S aureus 
counts were found along with very high ones. The microenviron-
ment of the skin also includes the factors dryness and osmolarity 
which undergo rapid changes and can influence bacterial growth. 
Low hydration was associated with high S aureus growth in our AD 
patients, whereas osmolarity is an interesting factor which we did 
not consider in our study.
As expected from the literature, TEWL was higher and hydration 
level was lower in AD patients and often associated with an elevated 
skin pH.14–16 Surprisingly, in our study AD and HE did not signifi-
cantly differ in skin pH which could be due to relatively high skin pH 
in HE in our study compared with previous studies and low number 
of participants.9,11 Furthermore, skin pH is known to be linked to dis-
ease severity and in our study only participants with mild-to-moder-
ate eczema were included.10,11
As previously described, skin pH cannot be easily altered sus-
tainably by the study emollients although a short-term change was 
observed (Figure S5).9,44 However, especially in AD, a temporary dif-
ference in skin pH was observed, hinting toward a reduced buffer 
capacity in AD. This is of great importance considering that many 
common skin care products have a rather basic pH.4 Compared to 
water baths, dilute bleach baths do not consistently reduce AD sever-
ity and S aureus load in vivo and are not antimicrobial in vitro.45,46 In 
the “Guidelines of care for the management of AD” from 2015, rather 
acidic skin care is advised, more recent publications confirm the ben-
efit of acidification of the skin for improved barrier function in murine 
models.47–52 Even a preventive potential was suggested.49,51 Derived 
from the results of our study and other previous findings,49,51,52 prod-
ucts with even lower pH than 5.5 might be needed to change skin sur-
face pH effectively. Alternatively, a more continuous application 51 by 
increasing the frequency of application could furthermore contribute 
to reach more sustainable changes in skin physiology.
Even though this is a pilot study, we achieve statistical power due 
to the study design with intra-individual controls in a double-blinded 
fashion with frequent longitudinal sampling. However, our findings 
must be confirmed in a larger validation study.
Slightly acidic emollients are already a fixed tool in the therapy 
of AD.4,53 However, according to our results and as expected, basic 
skin care cannot control disease severity and underlines that basic 
skin care cannot be the only but a central tool in disease manage-
ment. If further studies with a larger number of patients confirm the 
predictive assumptions of S aureus abundances in relation to clinical 
symptoms, it could become a helpful tool for planning therapeutic 
options in AD.
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